Gilead to Buy Forty Seven for $4.9 Billion for Cancer Drug

(Bloomberg) -- Gilead Sciences Inc. agreed to buy Forty Seven Inc. for about $4.9 billion to advance into one of the hottest areas of pharmaceutical research: cancer treatments that harness the imm...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.